LONDON, March 29, 2017 -- APCER Life Sciences, the truly global provider of safety, medical, regulatory and technology services, announced today that it will now offer Quality Assurance (QA) Auditing as a stand-alone service. The launch of QA Auditing and Consultancy services from APCER makes available resources knowledgeable in the complex ecosystem of international regulations, internal practices, and external relationships that companies in the pharmaceutical industry seek to ensure global compliance.
“Today’s announcement is really a formalization of a capability that many of our current clients have already taken advantage of,” said Michael Britt, Head of the EU business unit for APCER Life Sciences. “We have grown our global Quality and Compliance organization to the size where we feel confident to offer our specialized expertise to the industry as a stand-alone service apart from support of our operational clients in clinical safety, post-marketing pharmacovigilance, and medical affairs.”
APCER will offer a wide range of audits, such as Good Pharmacovigilance Practice, Good Clinical Practice, and Good Manufacturing Practice, as well as Information Technology & Computer Systems Validation and the increasingly important Vendor Audit. Consultancy in the areas of Quality Risk Management, Inspection Preparation & Training, Mock Inspections, Gap Analysis, Quality Management Systems, and Learning Management is also available.
“Our QA Auditing and Consultancy services draw on the experience of a global team of expert auditors and other QA professionals to help pharmaceutical companies meet their regulatory obligations,” said Luke Keitel, Global Head of Quality and Compliance at APCER Life Sciences. “The offering is in direct response to the escalating complexity and cost of compliance that has driven organisations to outsource more of their audits to specialist service providers."
The announcement of QA Auditing and Consultancy services coincides with the opening of the DIA EuroMeeting 2017, an annual forum that brings together industry, academia, regulators, and patient representatives for thought-provoking sessions and candid discussion of common challenges. Representatives of APCER Life Sciences, including Michael Britt and Luke Keitel, will be on hand today through Friday, March 31, to debut the offering at Stand E10 in the Scottish Exhibition and Conference Centre in Glasgow, Scotland.
About APCER Life Sciences
APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources to ensure that patients receive the safest, most effective therapies possible.
To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit www.apcerls.com; and contact APCER at one of their global offices.
Contact for APCER Life Sciences: Jill Notte 609-436-4714 [email protected]


Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
AFT Leaves X Over AI-Generated Images of Minors
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 



